Tech Transfer Central
Tech Transfer eNews

Tech Transfer E-News provides a weekly round-up of current news and information in the world of tech transfer, delivered every Wednesday (sign up here). It is published by Technology Transfer Tactics newsletter, which is available as a monthly subscription. For more information or to order a subscription click here, or for a sample issue, click here.

U of Miami licenses out eye infection treatment to Provectus Biopharmaceuticals

The University of Miami and Provectus Biopharmaceuticals have entered into an exclusive global license agreement to commercialize a novel therapy for the treatment of eye infections.

Developed by U Miami researchers, the licensed technology is a photodynamic antimicrobial therapy (PDAT) targeting bacterial, fungal, and parasitic infections of the eye.

Through the agreement, Provectus may form a start-up to commercialize the technology in combination with a formulation of the company’s proprietary rose bengal sodium (RBS) active pharmaceutical ingredient, which was developed at the Ophthalmic Biophysics Center (OBC), part of the University of Miami’s Bascom Palmer Eye Institute (BPEI).

Under the terms of the license agreement, the university would be a minority equity shareholder in the new start-up.

“Rose bengal PDAT is the result of a lot of hard work by cross-disciplinary contributors at the University of Miami,” says Jean-Marie Parel, director of OBC. “We look forward to working with Provectus to deliver this groundbreaking treatment to patients worldwide.”

Ed Pershing, chairman of Provectus’ Board of Directors, comments, “We look forward to working with Bascom Palmer and the OBC to reduce or eliminate the risk of blindness and impaired vision from eye infections for millions of people around the world through the promise of rose bengal sodium PDAT.”

Source: GlobeNewswire

Posted under: Tech Transfer e-News